H7T2.F HUTCHMED (CHINA) LS-1

Healthcare Pharmaceuticals Frankfurt Exchange
2.54 EUR
Close of Nov 12, 2026
1.65 2.86
Market cap
EUR 2.21B
P/E
127.0x
P/B
1.94x
ROE
36.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is H7T2.F undervalued?

Graham number

The Graham number of HUTCHMED (CHINA) LS-1 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HUTCHMED (CHINA) LS-1 fundamental analysis

No fundamental analysis for HUTCHMED (CHINA) LS-1 yet.

HUTCHMED (CHINA) LS-1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HUTCHMED (CHINA) LS-1

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), …

Full company profile